CoChat

Microscaled proteogenomic methods for precision oncology

Open access
Satpathy, Shankha, Jaehnig, Eric J., Krug, Karsten, Kim, Beom-Jun, Saltzman, Alexander B., Chan, Doug W., Holloway, Kimberly R., Anurag, Meenakshi, Huang, Chen, Singh, Purba, Gao, Ari, Namai, Noel, Dou, Yongchao, Wen, Bo, Vasaikar, Suhas V., Mutch, David, Watson, Mark A., Ma, Cynthia, Ademuyiwa, Foluso O., Rimawi, Mothaffar F., Schiff, Rachel, Hoog, Jeremy, Jacobs, Samuel, Malovannaya, Anna, Hyslop, Terry, Clauser, Karl R., Mani, D. R., Perou, Charles M., Miles, George, Zhang, Bing, Gillette, Michael A., Carr, Steven A., Ellis, Matthew J. · 2020 · Nature Communications
Cited by 111

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Cancer proteogenomics promises new insights into cancer biology and treatment efficacy by integrating genomics, transcriptomics and protein profiling including modifications by mass spectrometry (MS). A critical limitation is sample input requirements that exceed many sources of clinically important material. Here we report a proteogenomics approach for core biopsies using tissue-sparing specimen processing and microscaled proteomics. As a demonstration, we analyze core needle biopsies from ERBB2 positive breast cancers before and 48–72 h after initiating neoadjuvant trastuzumab-based chemotherapy. We show greater suppression of ERBB2 protein and both ERBB2 and mTOR target phosphosite levels in cases associated with pathological complete response, and identify potential causes of treatment resistance including the absence of ERBB2 amplification, insufficient ERBB2 activity for therapeutic sensitivity despite ERBB2 amplification, and candidate resistance mechanisms including androgen receptor signaling, mucin overexpression and an inactive immune microenvironment. The clinical utility and discovery potential of proteogenomics at biopsy-scale warrants further investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-14381-2

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 111

Metadata

Authors
Satpathy, S., Jaehnig, E. J., Krug, K., Kim, B.-J., Saltzman, A. B., Chan, D. W., Holloway, K. R., Anurag, M., Huang, C., Singh, P., Gao, A., Namai, N., Dou, Y., Wen, B., Vasaikar, S. V., Mutch, D., Watson, M. A., Ma, C., Ademuyiwa, F. O., Rimawi, M. F., Schiff, R., Hoog, J., Jacobs, S., Malovannaya, A., Hyslop, T., Clauser, K. R., Mani, D. R., Perou, C. M., Miles, G., Zhang, B., Gillette, M. A., Carr, S. A., & Ellis, M. J.
Venue
Nature Communications
Published
2020-01-27
Volume
11
Issue
1
Pages
532-532
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3001564104
Cited by
111
References
12
FWCI
6.44
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Microscaled proteogenomic methods for precision oncology. https://app.cochat.ai/papers/10.1038/s41467-020-14381-2
The paper
Satpathy, S., Jaehnig, E. J., Krug, K., Kim, B.-J., Saltzman, A. B., Chan, D. W., Holloway, K. R., Anurag, M., Huang, C., Singh, P., Gao, A., Namai, N., Dou, Y., Wen, B., Vasaikar, S. V., Mutch, D., Watson, M. A., Ma, C., Ademuyiwa, F. O., . . . Ellis, M. J. (2020). Microscaled proteogenomic methods for precision oncology. Nature Communications. https://doi.org/10.1038/s41467-020-14381-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.